Chris Cooley
Stock Analyst at Stephens & Co.
(3.10)
# 1,249
Out of 4,712 analysts
57
Total ratings
70%
Success rate
45.43%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $54.91 | -23.51% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $208.51 | +79.85% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $91.93 | +25.10% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $84.89 | +8.38% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $17.41 | -31.07% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $16.46 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $46.07 | +95.35% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $205.56 | +31.35% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $149.94 | -54.65% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $15.92 | +182.66% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $177.98 | +54.51% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $24.29 | +52.33% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $77.77 | -22.85% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $15 | $0.35 | +4,150.50% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $89.32 | -60.82% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $261.07 | -68.97% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $54.91
Upside: -23.51%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $208.51
Upside: +79.85%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $91.93
Upside: +25.10%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $84.89
Upside: +8.38%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $17.41
Upside: -31.07%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $16.46
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $46.07
Upside: +95.35%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $205.56
Upside: +31.35%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $149.94
Upside: -54.65%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $15.92
Upside: +182.66%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $177.98
Upside: +54.51%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $24.29
Upside: +52.33%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $77.77
Upside: -22.85%
Mar 23, 2020
Maintains: Overweight
Price Target: $45 → $15
Current: $0.35
Upside: +4,150.50%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $89.32
Upside: -60.82%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $261.07
Upside: -68.97%